Targeting BCMA in Multiple Myeloma: Evidence-Based Guidance for Current and Near-Future Clinical Integration

Download All
Learn how experts apply practice-changing clinical data to integrate the use of BCMA-targeted agents for their patients with multiple myeloma, with focused commentaries, a healthcare professional resource, and a module with downloadable slides.
Sagar Lonial, MD
Nina Shah, MD

ClinicalThought

Learn how experts incorporate BCMA-directed therapies for multiple myeloma into their practice.

Nina Shah, MD Released: February 2, 2022

We’ve heard a great deal about BCMA-targeted CAR T-cell therapy and antibody–drug conjugates for R/R MM. In this commentary, Dr Sagar Lonial discusses how BCMA-targeted bispecific therapies will fit in to the treatment landscape.

Sagar Lonial, MD Released: April 14, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings